BioAge Labs vs Palatin Technologies
BIOA and PTN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIOA and PTN compare
BioAge Labs is the larger company, worth 23 times as much as Palatin Technologies ($255M against $11.1M).
BioAge Labs scores higher on the StockData Score (8 against 6 for Palatin Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIOA | PTN |
|---|---|---|
| Size and price | ||
| Market cap | $255M | $11.1M |
| Share price | $5.55 | $6.23 |
| Change, 1 year | −30.7% | −43.6% |
| Change, 5 years | – | −98.6% |
| Beta (5Y) | 1.80 | 0.77 |
| Employees | 62 | 25 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 29.6× | – |
| P/B | 0.7× (better) | 1.7× |
| FCF yield | −40.4% (better) | −122% |
| Growth | ||
| Revenue growth (TTM) | 45.3% | – |
| Profitability | ||
| Operating margin | −1402% | – |
| Net margin | −1254% | – |
| FCF margin | −1198% | – |
| Return on equity | −34.6% (better) | −878% |
| Return on invested capital | −325% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −913.2× (better) | −1288.8× |
| Current ratio | 15.51 (better) | 4.61 |
| Altman Z-score | 5.47 (better) | −75.61 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −152% |
| Shareholder yield | 0.00% (better) | −152% |
| Ownership | ||
| Held by institutions | 82.2% | 38.5% |
| Held by insiders | 21.9% | 20.6% |
| Insider net buying, 12 months | −$7.8M | −$9.5K (better) |
| Short interest, % of float | 10.4% | 20.9% |
Go deeper
- BIOA stock overview
- BIOA income statement
- BIOA valuation and score
- PTN stock overview
- PTN income statement
- PTN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.